Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.

By H. Kantarjian, D. DeAngelo, M. Stelljes, G. Martinelli, M. Liedtke, W. Stock, N. Gökbuget, S. O'brien, Kongming Wang, Tao Wang and 4 more. New England Journal of Medicine, 2016

1,177 citations recorded by the source corpus.

Subfields: Oncology, Public Health, Environmental and Occupational Health

View Paper: https://www.semanticscholar.org/paper/b2e5765fa56bf7cd56e66b8576fdfbb26ffd324b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. N. Shah
2. T. Fry

Citations in the corpus

• Antibody drug conjugate: the “biological missile” for targeted cancer therapy (2022, background): “4% was observed in alternative chemotherapy group.(168,169) The AEs ≥ grade 3 in the inotuzumab ozogamicin arm include neutropenia (47%), thrombocytopenia (41%), leukopenia (27%), and febrile neutropenia (27%).”
• CD22-CAR T Cells Induce Remissions in CD19-CAR Naïve and Resistant B-ALL (2017, positive): “29 However, liver toxicity limited the dose intensity that could be safely delivered and the agent is associated with higher rates of veno-occlusive disease following subsequent HSCT. 24,34 We generated a novel CAR targeting CD22, which we optimized by comparing potency across multiple scFvs and…”